虽然BRAFV600E突变转移性结直肠癌患者面临极高的未满足医疗需求，但迄今为止，针对这部分初治患者的生物标志物驱动治疗产品尚未得到批准。此次辉瑞的组合疗法获得FDA加速批准，不仅为患者带来了全新的治疗选择，也为医药行业研究和开发高效疗法提供了新的方向与动力。

Introduction: BRAFV600E mutation (BRAF mut) is common in papillary thyroid cancer (PTC), and most patients have an excellent outcome. However, a TERT-promoter mutation (pTERT mut) in the presence of ...

Boundless Bio’s freshman year on the public markets hasn’t been easy, with “modest” layoffs in the summer followed by news ...

▎药明康德内容团队编辑（来源：北京大学）红细胞生成是维持机体正常生理活动和血液系统正常功能的重要过程。红细胞生成异常往往会导致贫血，并与多种遗传性疾病密切相关。然而，目前用于治疗贫血的药物选择极为有限。例如，先天性再生障碍型贫血（如Diamond-B ...

Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno ...

Boundless has been evaluating BBI-825, an oral RNR inhibitor, in the Phase 1/2 STARMAP clinical trial for patients with solid tumors, including those with BRAFV600E or KRASG12C mutated colorectal ...

寒冷刺骨的冬天，手捧一杯热腾腾的奶茶，甜蜜从嘴巴滑到心里，仿佛一切疲惫都被融化了。但你知道吗？让奶茶“甜蜜蜜”的那个关键成分——果糖，竟是肿瘤生长的“幕后推手”！冬日的这份“小确幸”，可能正藏着“大隐患”。 图源：pixabay ...

我们的身体中每天通过红细胞生成（Erythropoiesis）过程产生大约2×1011个红细胞，这也是导致贫血的各种血液系统疾病中受损的关键生理过程。红系祖细胞，尤其是爆式红系集落形成单位（BFU-E）和红系集落形成单位（CFU-E）的供应和功能，对红细胞的生成至关重要。

目前已经明确几乎所有BAVM的发生均与基因突变有关，因此 对BAVM患者及亲属进行基因筛查的必要性是目前需要迫切关注的问题 。研究数据表明，大约90%的散发BAVM病例的病因为KRAS或BRAF体细胞激活突变 [7] 。

Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for developme ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...